CTRI/2020/07/026368尚未招募未知
Secondary attack rate of Covid-19 during pandemic in Pune City, Maharashtra
I0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •All the contacts laboratory confirmed Covid 19 cases will be enrolled after taking informed consent.In case study subject is less than 18 years , informed consent will be taken from the parents/guardian and the assent will be taken from the subject.
排除标准
- •All contacts of laboratory confirmed Covid 19 cases from area outside Pune city.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of study drug OMS721 in adults withthrombotic microangiopathies.Three forms of thrombotic microangiopathies (TMA):- atypical hemolytic uremic syndrome (aHUS).- hematopoietic stem cell transplant (HSCT)-associated TMA.- thrombotic thrombocytopenic purpura (TTP).MedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-001032-11-ITOMEROS CORPORATIO89
进行中（未招募）
1 期
A Study to Assess how Safe and Effective HBI-3000 is for the Conversion of Atrial Fibrillation (AF) of Recent OnsetSustained atrial fibrillation (AF) of over 2 hours and <72 hours duration up to the time of dosing, eligible for cardioversion (electrical and pharmacologic)MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2022-001021-74-PLHUYABIO International, LLC150
进行中（未招募）
1 期
A study to determine the safety profile and recommended dose of SNS-062 for further evaluation of a new cancer agent to treatment relapsed or resistant B-lymphoid cancers.Male or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequent BTK inhibition using SNS-062.MedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.1Level: HLTClassification code 10047802Term: Waldenstrom's macroglobulinaemiasSystem Organ Class: 100000004851MedDRA version: 21.0Level: LLTClassification code 10008948Term: Chronic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2018-000108-41-ESSunesis Pharmaceuticals, Inc.174
进行中（未招募）
1 期
A study to determine the safety profile and recommended dose of SNS-062 for further evaluation of a new cancer agent to treatment relapsed or resistant B-lymphoid cancersMale or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequent BTK inhibition using SNS-062.MedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.1Level: HLTClassification code 10047802Term: Waldenstrom's macroglobulinaemiasSystem Organ Class: 100000004851MedDRA version: 20.1Level: LLTClassification code 10008948Term: Chronic leukemiaSystem Organ Class: 100000004864EUCTR2018-000108-41-GBSunesis Pharmaceuticals, Inc.124
进行中（未招募）
1 期
A study to determine the safety profile and recommended dose of SNS-062 for further evaluation of a new cancer agent to treatment relapsed or resistant B-lymphoid cancersMale or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequent BTK inhibition using SNS-062.MedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.1Level: HLTClassification code 10047802Term: Waldenstrom's macroglobulinaemiasSystem Organ Class: 100000004851MedDRA version: 21.0Level: LLTClassification code 10008948Term: Chronic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2018-000108-41-ITSunesis Pharmaceuticals, Inc.124